An open label, single arm study out of China is evaluating the combined use of pemetrexed, platinum-based therapy, bevacizumab, and durvalumab for 4–6 cycles followed by maintenance therapy with durvalumab +/− bevacizumab for patients with EGFR-mutant NSCLC that have progressed on first-line osimertinib (NCT04517526). Here, EGFR is linked to non-small cell lung carcinoma.